Programmable Bio-Nano-Chip Systems for Serum CA125 Quantification: Toward Ovarian Cancer Diagnostics at the Point-of-Care
Archana Raamanathan(The University of Texas at Austin), John T. McDevitt(New York University), Robert C. Bast(The University of Texas MD Anderson Cancer Center), Wieslaw B. Furmaga(Bexar County Medical Examiner's Office), Karen H. Lu(The University of Texas MD Anderson Cancer Center), Pierre N. Floriano(Rice University), Nicolaos Christodoulides(Rice University), Spencer W. Redding(The University of Texas at San Antonio Health Science Center), Glennon W. Simmons(Rice University)
Cited by 48
Related Papers
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
|The Lancet|2010|2.3k
Reactivity of a monoclonal antibody with human ovarian carcinoma.
|Journal of Clinical Investigation|1981|1.7k
Rethinking ovarian cancer: recommendations for improving outcomes
|Nature reviews. Cancer|2011|1.5k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k